MedTrace Logo

Comparative Research Among 3 Action Protocol in Other to Approach Chronic Patellar Tendinopathy

NCT02498795 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-12-04

No results posted yet for this study

Summary

The accomplishment of a treatment with Intratissue Percutaneous Electrolysis of additional form to the accomplishment of eccentric exercise's program in patients with chronic patellar tendinopathy is more effective than the accomplishment of an additional treatment with dry needling or eccentric exercise's program realized of isolated form.

Conditions

  • Tendinopathy

Interventions

OTHER

Group of Dry Needling

Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.

OTHER

Group of Electrolysis

Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.

OTHER

Control Group

Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.

Sponsors & Collaborators

  • Universidad San Jorge

    collaborator OTHER

  • Universidad de Zaragoza

    lead OTHER

Principal Investigators

  • Eva Gómez-Trullén, PhD · Universidad de Zaragoza

  • Pablo Herrero, PhD · Universidad San Jorge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-12-31
Completion
2020-05-02

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02498795 on ClinicalTrials.gov